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ihe incidence and prevalence of coronary heart disease and
therosclerotic diseases in noncoronary beds are higher in
ost-menopausal than in pre-menopausal women. Whether
his higher cardiovascular risk is a function of aging, a
onsequence of menopause and its associated loss of endog-
nous estrogen, or both has been debated in the literature
or many years (1–3). To add to the complexity, investiga-
ors recently suggested that the timing of menopause itself
ould be influenced by the cardiovascular risk milieu (4).
See page 2366
Trying to sort out the relative contribution of 2 concur-
ent and intimately linked processes such as aging and
enopause (ovarian aging) to cardiovascular disease, which
s multifactorial in origin, is methodologically challenging.
ross-sectional studies cannot distinguish between the 2
rocesses. Previous longitudinal studies often had limita-
ions relating to the definition of menopause; the exact
iming of the final menstrual period; the lack of concurrent
easurement of hypothalamic and reproductive hormones
o distinguish menopause from other causes of amenorrhea;
nadequate capture of multiple risk markers at frequent
ntervals in the critical period between late pre-menopause,
erimenopause, and early menopause; and the lack of
oncurrent measurement of covariates that could influence
he relationship between menopause and cardiovascular risk
actors including lifestyle measures and medications. Impor-
antly, previous studies were generally limited to samples of
aucasian women.
In this issue of the Journal, Matthews et al. (5) attempt to
isentangle the influence of aging and menopause on
ardiovascular risk factors in a subset of 1,054 women
nrolled in SWAN (Study of Women’s Health Across the
ation), a multicenter, prospective cohort study of initially
re-menopausal or early perimenopausal women of diverse
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.s
From the Division of Cardiovascular Disease, Department of Medicine, University
f Alabama at Birmingham, Birmingham, Alabama.thnicity. SWAN participants included in the current anal-
sis were not taking hormone therapy before menopause;
anged in age from 42 to 52 years; were free of stroke, heart
isease, and diabetes at entry; were followed for 9 years; and
eached their final menstrual period during follow-up. The
uthors serially measured blood pressure, lipids and lipopro-
eins, hemostatic factors, insulin and glucose, and high-
ensitivity C-reactive protein and concluded that only total
holesterol, low-density lipoprotein cholesterol (LDL-C),
nd apolipoprotein B (apo B) demonstrated increases in the
-year interval before and after the final menstrual period
hat were consistent with menopause-induced changes.
igh-density lipoprotein cholesterol (HDL-C) and apo
-I changes were also better described by the menopause
odel than by the aging model, but the greatest increase in
DL-C and apo A-I levels occurred before the 1-year
nterval surrounding the final menstrual period. The other
isk factors changed in a linear pattern consistent with
hronologic aging: triglycerides, lipoprotein (a), insulin,
actor VIIc, and systolic blood pressure increased; diastolic
lood pressure, tissue plasminogen activator antigen, fibrin-
gen, and high-sensitivity C-reactive protein did not
hange; and, somewhat unexpectedly, glucose and plasmin-
gen activator inhibitor decreased over time. Importantly,
he investigators did not find any heterogeneity by ethnic
roup. Major strengths of the present analysis include the
areful prospective characterization of the timing of the final
enstrual period, frequent assessment of risk factors in
ultiple domains, ability to adjust for many covariates that
ould confound the analysis, the multiethnic composition of
he cohort, and the use of sophisticated modeling that
llows unequal times between measurements and unequal
umbers of measurements across women.
The lipid changes attributable to menopause reported in
his study deserve a closer look. Figure 2A and 2B of
atthews et al. (5) shows the changes in LDL-C and apo
over time and nicely demonstrate that both measures
ncrease from pre-menopausal levels and that the changes
re not linear (i.e., not consistent with an aging model). It
s noteworthy, however, that the curves for the 2 measures
eem to diverge after year 1 after the final menstrual period
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po B. This finding suggests that composition of the
ow-density lipoprotein (LDL) particles changed after the
nal menstrual period and that the particle number de-
reased while the cholesterol content per particle increased.
his is an unexpected finding because previous cross-
ectional studies suggested a shift toward smaller, denser
DL particles during the menopausal transition (6,7). It is
f note that the women in the previous studies had lower
po B levels both pre-menopausally and post-menopausally
han seen in the current study. Whether the impact of
enopause on LDL-C and LDL particle number differs by
aseline apo B level is unknown. A similar discrepancy
etween cholesterol and apoprotein trajectories is evident
or HDL-C and apo A-I, where apo A-I continues to
ncrease after the final menstrual period while HDL-C
evels decline (Fig. 2C and 2D of Matthews et al. [5]).
hese findings require confirmation in other contemporary
ongitudinal data sets. Assuming that there are discrepant
hanges in cholesterol and apoprotein levels after cessation
f menses, how should we best assess a woman’s cardiovas-
ular risk? Computation of the apo B/A-I ratio post-
enopause would convey a lower risk than computation of
he LDL-C/HDL-C ratio. It will be critically important to
losely follow the women in the SWAN study long term to
etermine which of these 2 measures better relates to actual
ardiovascular events. Such follow-up could also tell us
hether we need to only focus on the risk factor values
chieved after the menopausal transition is completed or
hether the degree and slope of change during the transi-
ion carry additional prognostic information.
Triglycerides in this cohort increased 1.75% annually in a
attern consistent with chronologic aging. Given that me-
abolism of HDL and triglyceride-rich lipoproteins is
losely linked in general and significantly influenced by
strogen, it is a bit puzzling that changes in HDL-C and
po A-I would be related to menopause, whereas triglycer-
de changes would be driven solely by chronologic aging. It
s possible that the greater variability in triglyceride mea-
urements could have masked a menopausal effect, but
etabolic changes that alter the relationship between trig-
ycerides and HDL at the time of menopause cannot be
xcluded and deserve further exploration in detailed longi-
udinal kinetic studies.
Blood pressure, hemostatic markers, high-sensitivity
-reactive protein, and glucose and insulin were not influ-
nced by menopause in this cohort. Should we then con-
lude that the impact of menopause is limited to adverse
ffects on lipids and that CHD risk in post-menopausal
omen is otherwise driven by chronologic aging? I believe
hat this would be premature. Both in vitro studies and in
ivo studies in animals and humans show that estrogens
ave vascular effects (genomic and nongenomic) that could Knfluence susceptibility to atherosclerosis and future cardio-
ascular events (8). Reproductive hormones also have a
ajor impact on bone remodeling and calcium homeostasis
nd could thus influence vascular calcification independent
f alterations in serum markers measured in the current
tudy (9,10). To determine the relative contributions of
hronologic aging and menopause to overall cardiovascular
isk, future studies should not only assess cardiovascular risk
actors but also assess vascular structure and function lon-
itudinally in the context of careful characterization of the
enopausal transition and while controlling for important
ovariates.
For now, the major take-home point for the clinician is
hat risk factor levels do indeed change around the time of
enopause, some related to chronologic aging and some
elated to the menopausal transition itself. Women should
e made aware that their cardiovascular risk is likely to
ncrease during this period and should be counseled to
mphasize therapeutic lifestyle changes to combat such
ncreases. It may be prudent to increase the frequency of risk
actor monitoring during this time to identify women in a
imely fashion who may benefit from pharmacologic man-
gement of their risk factors beyond lifestyle modification.
eprint requests and correspondence: Dr. Vera Bittner, LHRB
10, UAB Station, Birmingham, Alabama 35294. E-mail:
bittner@uab.edu.
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